AFTD and ADDF Announce Major New Investments in FTD Research



AFTD and The Alzheimer’s Drug Discovery Foundation (ADDF) announced today four new research awards to scientists looking for novel ways to diagnose and treat FTD. The awards were announced this week to help mark World FTD Awareness Week 2020.

“Our partnerships with other forward-thinking groups like AFTD increase the impact of our funding and leverage our combined expertise to find dementia treatments faster,” said Howard Fillit, MD, the ADDF’s Founding Executive Director and Chief Science Officer. “Today’s awards showcase our strategy of maintaining a diverse research portfolio that addresses the many biological processes that cause FTD, Alzheimer’s, and other forms of dementia.”

Including today’s awards of more than $3.4 million, the ADDF/AFTD partnership, which offers research support from three different funding streams, has awarded $8.7 million to 39 FTD research projects.

“The scope of today’s awards demonstrates the commitment of both organizations to supporting the best science available and addressing the multiple pathways implicated in FTD and other forms of dementia,” said Susan L-J Dickinson, AFTD’s Chief Executive Officer. “During this week of global FTD awareness, these awards provide renewed hope for a future free of this disease.”

For more information about the individual awards, please read the ADDF’s press release.